Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 14/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.43 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.43 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18794977 | 0.99 | BTK (0.58) | BTKHSD17B10KLKB1EGLN1GRIN1 | |
| Lithium SCHEMBL18794982 | 0.98 | BTK (0.57) | BTKHSD17B10KLKB1EGLN1GRIN1 | |
| SCHEMBL21953682 | 0.92 | BTK (0.58) | BTKHSD17B10KLKB1EGLN1 | |
| SCHEMBL18816828 | 0.88 | BTK (0.57) | BTKKLKB1 | |
| SCHEMBL20549625 | 0.87 | BTK (0.59) | BTKHSD17B10KLKB1EGLN1 | |
| SCHEMBL21953537 | 0.85 | BTK (0.56) | BTKKLKB1 | |
| SCHEMBL23769517 | 0.85 | BTK (0.60) | BTKHSD17B10KLKB1EGLN1 | |
| SCHEMBL18816755 | 0.85 | BTK (0.60) | BTKHSD17B10KLKB1EGLN1 | |
| SCHEMBL18816736 | 0.85 | BTK (0.60) | BTKHSD17B10KLKB1EGLN1 | |
| SCHEMBL20549644 | 0.85 | BTK (0.60) | BTKHSD17B10KLKB1EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3368524-B1 | HETEROARYLCARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2021-08-18 | — | — | EP | disclosed |
| US-10640486-B2 | Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-05-05 | — | — | US | disclosed |
| US-20180319771-A1 | HETEROARYLCARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10640486-B2 | Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors | KLKB1, BDKRB1, BDKRB2 | BTK 3335/4885HSD17B10 907/4885KLKB1 1/4885 |
| US-20180319771-A1 | HETEROARYLCARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | KLKB1, BDKRB1, BDKRB2 | BTK 3335/4885HSD17B10 907/4885KLKB1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.